Janssen COVID-19 Vaccine (Ad26.COV2-S (recombinant))

• On 19 April 2021, the Food and Drug Administration (FDA) issued authorization granting Johnson & Johnson (Philippines), Inc. the emergency use approval of Janssen COVID-19 Vaccine.

                           Fact Sheet for Healthcare Providers Administering the Vaccine
                             English     Tagalog

                           Fact Sheet for Recipients and Caregivers
                             English     Tagalog

• The Janssen COVID-19 Vaccine is authorized on the basis of regulatory reliance to the United States Food and Drug Administration.
• Information regarding Janssen COVID-19 Vaccine is being updated regularly and is available here.
• Information on the safety of Janssen COVID-19 Vaccine is discussed in their comprehensive Risk Management Plan.
• For more information on reporting side effects, click here.